Case Type: Mergers & Acquisitions

Atlas Technical Consultants, Inc. (NASDAQ: ATCX), relating to its proposed sale to GI Partners. Under the terms of the agreement, ATCX shareholders are expected to receive $12.25 in cash per share they own.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), relating to its proposed acquisition by Sun Pharmaceutical Industries Limited. Under the terms of the tender offer, CNCE shareholders are expected to receive $8.00 in cash and one non-tradeable CVR worth a deferred $3.50 in cash per share they own.

Leap Therapeutics, Inc. (NASDAQ: LPTX), relating to its proposed purchase of Flame Biosciences, Inc. Under the terms of the agreement, LPTX will issue shares of common stock and Series X non-voting convertible preferred stock to Flame shareholders, with each Series X share convert to 1000 shares of common stock upon approval of the transaction.

Volta Inc. (NYSE: VLTA), relating to its proposed sale to Shell USA. Under the terms of the agreement, VLTA shareholders are expected to receive $0.86 in cash per share they own.

Calyxt, Inc. (NASDAQ: CLXT), relating to its proposed merger with Cibus. Under the terms of the agreement, Cibus shareholders are expected to receive new shares of CLXT, with CLXT shareholders expected to own approximately 5% of the combined company.

Angion Biomedica Corp. (NASDAQ: ANGN), relating to its proposed merger with Elicio Therapeutics. Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.

Golden Matrix Group, Inc. (NASDAQ: GMGI), relating to its proposed merger with MeridianBet Group.

Duck Creek Technologies, Inc. (NASDAQ: DCT), relating to its proposed sale to Vista Equity Partners. Under the terms of the agreement, DCT shareholders are expected to receive $19.00 in cash per share they own.

Paya Holdings Inc. (NASDAQ: PAYA), relating to its proposed sale to Nuvei Corp. Under the terms of the agreement, PAYA shareholders are expected to receive $9.75 in cash per share they own.

Albireo Pharma, Inc. (NASDAQ: ALBO), relating to its proposed sale to Ipsen. Under the terms of the agreement, ALBO shareholders are expected to receive $42.00 in cash per share they own, plus one Contingent Value Right worth a deferred $10.00 per share.